Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sosimerasib + IN10018 vs Standard Therapy in 1L Advanced/Metastatic Non-squamous NSCLC with KRAS G12C Mutation
NCT07833202Phase 3Not yet recruiting
- Sponsor
- Jeyou Pharmaceutical
- Start
- Oct 2026
- Primary completion
- Apr 2029
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of sosimerasib and ifebemtinib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Jeyou Pharmaceutical. Primary endpoint: Progression-Free Survival at 30 months. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
sosimerasibifebemtinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07833202.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07833202.